SFDA Hosts Drug Innovation Conference To Promote Pharmaceutical Advancements And Security

The Saudi Food and Drug Authority (SFDA) inaugurated the Drug Innovation Conference at its Riyadh headquarters, aligning with World Creativity and Innovation Day. SFDA CEO Dr. Hisham bin Saad Aljadhey highlighted innovation as vital for a sustainable pharmaceutical system, enhancing drug security and scientific progress. He noted Saudi Arabia's strides in research, regulatory, and industrial development, supporting the Health Sector Transformation Program under Vision 2030.

Dr. Aljadhey emphasized collaboration with public and private sectors to foster an innovation-friendly environment. This aims to empower national industries in creating promising pharmaceutical products. The conference drew representatives from key ministries and institutions, underscoring its significance in shaping the future of drug innovation both locally and globally.

Sessions at the conference explored government roles in pharmaceutical innovation support, future drug development trends, AI applications in treatment discovery, and regulatory aspects of innovative treatments. Initiatives by the UN World Health Organization (WHO) were also reviewed, providing a comprehensive overview of global efforts in this field.

The SFDA seeks to bolster its support for research and innovation through this conference. It aims to reaffirm its mission as a global leader in enhancing pharmaceutical quality and safety. This aligns with its Fourth Strategy, focusing on fields under its supervision.

Attendees included representatives from the Ministry of Health, Ministry of Industry and Mineral Resources, Ministry of Investment, Saudi Authority for Intellectual Property, Saudi National Institute of Health, King Saud University, and the Research, Development, and Innovation Authority. Their presence highlights the collaborative effort required to anticipate future drug innovation trends.

The conference serves as a platform for discussing how government authorities can support pharmaceutical advancements. It also examines how AI can be leveraged for discovering new treatments while addressing regulatory challenges associated with innovative therapies.

The SFDA's commitment to supporting research is evident through its initiatives aimed at fostering an environment conducive to innovation. By collaborating with various sectors, it strives to empower national industries in developing cutting-edge pharmaceutical solutions that meet global standards.

With inputs from SPA